keyword
MENU ▼
Read by QxMD icon Read
search

Acromegaly

keyword
https://www.readbyqxmd.com/read/27933171/active-postoperative-acromegaly-sustained-remission-after-discontinuation-of-somatostatin-analogues
#1
Cristina Alvarez-Escola, Jersy Cardenas-Salas
: In patients with active acromegaly after pituitary surgery, somatostatin analogues are effective in controlling the disease and can even be curative in some cases. After treatment discontinuation, the likelihood of disease recurrence is high. However, a small subset of patients remains symptom-free after discontinuation, with normalized growth hormone (GH) and insulin-like growth factor (IGF1) levels. The characteristics of patients most likely to achieve sustained remission after treatment discontinuation are not well understood, although limited evidence suggests that sustained remission is more likely in patients with lower GH and IGF1 levels before treatment withdrawal, in those who respond well to low-dose treatment, in those without evidence of adenoma on an MRI scan and/or in patients who receive long-term treatment...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27932856/three-dimensional-soft-tissue-analysis-of-the-hand-a-novel-method-to-investigate-effects-of-acromegaly
#2
Inge A Hoevenaren, M A E M Wagenmakers, S H P P Roerink, R T Netea-Maier, D J O Ulrich, Thomas J J Maal
BACKGROUND: Acral overgrowth is a highly common clinical sign in patients with active acromegaly. To what extent this overgrowth persists after long-term remission of acromegaly is largely unknown. Using the new imaging technique of three-dimensional (3D) stereophotogrammetry, it is possible to accurately investigate soft tissue changes of the hand. The aim of the recent study was to compare the 3D soft tissue characteristics of the hands of patients in long-term remission of acromegaly to those of a healthy pair matched control group...
2016: European Journal of Plastic Surgery
https://www.readbyqxmd.com/read/27932529/effectiveness-of-first-line-pegvisomant-monotherapy-in-acromegaly-an-acrostudy-analysis
#3
Nicholas A Tritos, Philippe Chanson, Camilo Jimenez, Donna King, Peter J Jönsson, Anne Klibanski, Beverly M K Biller
OBJECTIVE: To examine the effectiveness and safety of primary pegvisomant monotherapy. DESIGN: Retrospective analysis of data extracted from ACROSTUDY (global observational outcomes study of patients with acromegaly treated with pegvisomant). METHODS: The earliest time to insulin-like growth factor 1 (IGF-1) normalization on pegvisomant monotherapy was determined. Both the proportion of patients who achieved IGF-1 normalization and the time to IGF-1 normalization on pegvisomant monotherapy were assessed...
February 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27932528/comorbidities-treatment-patterns-and-cost-of-illness-of-acromegaly-in-sweden-a-register-linkage-population-based-study
#4
Eva Lesén, Daniel Granfeldt, Aude Houchard, Jérôme Dinet, Anthony Berthon, Daniel S Olsson, Ingela Björholt, Gudmundur Johannsson
OBJECTIVE: Acromegaly is a complex endocrine disease with multiple comorbidities. Treatment to obtain biochemical remission includes surgery, medical therapy and radiation. We aimed to describe comorbidities, treatment patterns and cost-of-illness in patients with acromegaly in Sweden. DESIGN: A nationwide population-based study. METHODS: Patients with acromegaly were identified and followed in national registers in Sweden. Longitudinal treatment patterns were assessed in patients diagnosed between July 2005 and December 2013...
February 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27926659/macroprolactinomas-and-nonfunctioning-pituitary-adenomas-and-pregnancy-outcomes
#5
Kimberley Lambert, Kate Rees, Paul T Seed, Mandish K Dhanjal, Marian Knight, David R McCance, Catherine Williamson
OBJECTIVE: To examine the monitoring, management, and outcomes of pituitary tumors in pregnancy. METHODS: A national, prospective, observational, population-based case series study was conducted in all U.K. consultant-led obstetric units over 3 years using the U.K. Obstetric Surveillance System. To evaluate rates of adverse pregnancy outcomes, women with a macroprolactinoma (10 mm or greater) or nonfunctioning pituitary adenoma, diagnosed before or during pregnancy, were compared with two comparison groups: 1) a U...
December 2, 2016: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27922495/toxic-and-endocrine-myopathies
#6
Hans D Katzberg, Charles D Kassardjian
PURPOSE OF REVIEW: This article discusses the clinical features, pathophysiology, and management of toxic and endocrine myopathies. RECENT FINDINGS: Early detection and expeditious correction of metabolic disturbances in endocrinopathies such as Cushing syndrome, thyroid and parathyroid diseases, and acromegaly can minimize and prevent neurologic complications including myopathy. Recently proposed mechanisms of injury in patients with critical illness myopathy include inhibition of protein synthesis, mitochondrial dysfunction, disruption of the ubiquitin-proteasome system, oxidative stress, and disruption of intramuscular calcium homeostasis, which can cause a myosin-loss myopathy...
December 2016: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/27921427/-growth-hormone-axis-gh-igf1-and-glucose-metabolism
#7
Michal Kršek
Growth hormone is a hormone of anterior lobe of pituitary gland which possesses besides its growth promoting effects also many other various physiological effects including its regulatory influences on metabolism with glucose metabolism belonging to most important ones. The present article summarizes basic information about metabolic consequences of disturbed growth hormone secretion and their importance for clinical presentation and management.Key words: acromegaly - glucose - growth hormone - growth hormone deficiency - IGF1 - metabolism...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27913611/silent-somatotroph-tumour-revisited-from-a-study-of-80-patients-with-and-without-acromegaly-and-a-review-of-the-literature
#8
Laura Chinezu, Alexandre Vasiljevic, Jacqueline Trouillas, Marion Lapoirie, Emmanuel Jouanneau, Gérald Raverot
BACKGROUND: Silent somatotroph tumours are growth hormone (GH) immunoreactive (IR) pituitary tumours without clinical and biological signs of acromegaly. Their better characterisation is required to improve the diagnosis. MATERIALS AND METHODS: Twenty-one silent somatotroph tumours were compared to 59 somatotroph tumours with acromegaly. Tumours in each group were classified into GH and plurihormonal (GH/prolactin (PRL)/±thyroid-stimulating hormone (TSH)) and into densely granulated (DG) and sparsely granulated (SG) types...
February 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27910111/cystatin-c-and-epicardial-adipose-tissue-as-noninvasive-predictors-of-cardiovascular-risk-in-acromegaly
#9
Anna Aulinas, Iris Crespo, David Viladés, Ruben Leta, Eulàlia Urgell, Betina Biagetti, Susan M Webb, Elena Valassi
BACKGROUND: Acromegaly (ACRO) is associated with elevated cardiovascular risk, although the prevalence of coronary artery disease (CAD) is unclear. Increased epicardial adipose tissue (EAT) and elevated cystatin-C (Cys-C) levels are cardiovascular risk factors, also related to the progression of CAD in several populations. AIMS: To measure the severity and extent of CAD in patients with ACRO and to determine whether either EAT or Cys-C reflect higher cardiovascular risk in patients with ACRO than in healthy controls...
November 7, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27900635/somatostatin-and-dopamine-receptor-regulation-of-pituitary-somatotroph-adenomas
#10
REVIEW
Anat Ben-Shlomo, Ning-Ai Liu, Shlomo Melmed
Somatostatin and dopamine receptors are expressed in normal and tumoral somatotroph cells. Upon receptor stimulation, somatostatin and the somatostatin receptor ligands octreotide, lanreotide, and pasireotide, and to a lesser extent, dopamine and the dopamine analogs bromocriptine and cabergoline, suppress growth hormone (GH) secretion from a GH-secreting pituitary somatotroph adenoma. Somatostatin and dopamine receptors are Gαi-protein coupled that inhibit adenylate cyclase activity and cAMP production and reduce intracellular calcium concentration and calcium flux oscillations...
November 29, 2016: Pituitary
https://www.readbyqxmd.com/read/27900634/socs2-polymorphisms-are-not-associated-with-clinical-and-biochemical-phenotypes-in-acromegalic-patients
#11
Ericka B Trarbach, Alexander A Jorge, Felipe H Duarte, Marcello D Bronstein, Raquel S Jallad
PURPOSE: Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly. METHODS: Four SOCS2 SNPs (rs3782415, rs3816997, rs3825199 and rs11107116) were selected and genotyped by real-time PCR using specific Taqman probe assays...
November 29, 2016: Pituitary
https://www.readbyqxmd.com/read/27896545/safety-and-tolerability-of-pasireotide-long-acting-release-in-acromegaly-results-from-the-acromegaly-open-label-multicenter-safety-monitoring-program-for-treating-patients-who-have-a-need-to-receive-medical-therapy-access-study
#12
Maria Fleseriu, Elisha Rusch, Eliza B Geer
PURPOSE: Pasireotide long-acting release is a somatostatin analog that is indicated for treatment of patients with acromegaly. This analysis documents the safety of pasireotide long-acting release in patients with acromegaly enrolled in the ACCESS trial (ClinicalTrials.gov identifier: NCT01995734). METHODS: ACCESS is an open-label, multicenter, single-arm, expanded-treatment protocol designed to provide patients access to pasireotide long-acting release pending regulatory approval...
November 28, 2016: Endocrine
https://www.readbyqxmd.com/read/27874199/glucose-and-lipids-levels-with-lanreotide-autogel-120-mg-in-treatment-na%C3%A3-ve-patients-with-acromegaly-data-from-the-primarys-study
#13
Philippe J Caron, Stephan Petersenn, Aude Houchard, Caroline Sert, John S Bevan
OBJECTIVE: Impaired glycaemic control, characteristic of acromegaly, can be exacerbated by treatment with somatostatin analogues (SSAs), particularly those with multireceptor activity. We present data from the PRIMARYS study on the impact of the SSA lanreotide, associated with tumour volume and hormonal improvements, on glucose and other metabolic parameters in acromegaly. DESIGN: PRIMARYS was a 48-week open-label single-arm phase-3b study of lanreotide autogel 120mg/4 weeks...
November 22, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27868174/-acromegaly-recognition-of-a-rare-disease-in-psychiatric-practice
#14
A J de Kort, D Postulart, G A A M Wetzer, S H P P Roerink
Acromegaly is a rare disease which is caused by a tumour in the anterior lobe of the pituitary gland. The tumour stimulates excessive production of the growth hormone. As a result, all the organs and tissues in the body are induced to grow. This growth is responsible for a wide range of symptoms, some of which can be neuro-psychiatric.<br/> AIM: To promote the early detection of acromegaly so that treatment can be started as soon as possible and further damage can be prevented.<br/> METHOD: We searched PubMed for articles relating to quality of life and cognitive, psychological and psychiatric symptoms and personality changes associated with acromegaly...
2016: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/27864805/endocrine-hypertension-a-practical-approach
#15
REVIEW
Joseph M Pappachan, Harit N Buch
Elevated blood pressure resulting from few endocrine disorders (endocrine hypertension) accounts for a high proportion of cases of secondary hypertension. Although some features may be suggestive, many cases of endocrine hypertension remain silent until worked up for the disease. A majority of cases result from primary aldosteronism. Other conditions that can cause endocrine hypertension are: congenital adrenal hyperplasia, Liddle syndrome, pheochromocytomas, Cushing's syndrome, acromegaly, thyroid diseases, primary hyperparathyroidism and iatrogenic hormone manipulation...
November 19, 2016: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27858572/correlation-between-gh-and-igf-1-during-treatment-for-acromegaly
#16
Edward H Oldfield, John A Jane, Michael O Thorner, Carrie L Pledger, Jason P Sheehan, Mary Lee Vance
OBJECTIVE The relationship between growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly as serial levels drop over time after treatment has not been examined previously. Knowledge of this relationship is important to correlate pretreatment levels that best predict response to treatment. To examine the correlation between GH and IGF-1 and IGF-1 z-scores over a wide range of GH levels, the authors examined serial GH and IGF-1 levels at intervals before and after surgery and radiosurgery for acromegaly...
November 18, 2016: Journal of Neurosurgery
https://www.readbyqxmd.com/read/27857512/respiratory-manifestations-in-endocrine-diseases
#17
REVIEW
Codruţa Lencu, Teodora Alexescu, Mirela Petrulea, Monica Lencu
The control mechanisms of respiration as a vital function are complex: voluntary - cortical, and involuntary - metabolic, neural, emotional and endocrine. Hormones and hypothalamic neuropeptides (that act as neurotrasmitters and neuromodulators in the central nervous system) play a role in the regulation of respiration and in bronchopulmonary morphology. This article presents respiratory manifestations in adult endocrine diseases that evolve with hormone deficit or hypersecretion. In hyperthyroidism, patients develop ventilation disorders, obstructive and central sleep apnea, and pleural collection...
2016: Clujul Medical (1957)
https://www.readbyqxmd.com/read/27855229/late-presentation-of-acromegaly-in-medically-controlled-prolactinoma-patients
#18
Ekaterina Manuylova, Laura M Calvi, Catherine Hastings, G Edward Vates, Mahlon D Johnson, William T Cave, Ismat Shafiq
: Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion. The prevalence of acromegaly among patients with a newly diagnosed prolactinoma is unknown. Given the possibility of mixed GH and PRL co-secretion, the current recommendation is to obtain an insulin-like growth factor-1 (IGF-1) in patients with prolactinoma at the initial diagnosis. Long-term follow-up of IGF-1 is not routinely done...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27812777/acromegaly-clinical-features-at-diagnosis
#19
REVIEW
Lucio Vilar, Clarice Freitas Vilar, Ruy Lyra, Raissa Lyra, Luciana A Naves
BACKGROUND: Acromegaly is a rare and underdiagnosed disorder caused, in more than 95% of cases, by a growth hormone (GH)-secreting pituitary adenoma. The GH hypersecretion leads to overproduction of insulin-like growth factor 1 (IGF-1) which results in a multisystem disease characterized by somatic overgrowth, multiple comorbidities, physical disfigurement, and increased mortality. OBJECTIVE: This article aims to review the clinical features of acromegaly at diagnosis...
November 3, 2016: Pituitary
https://www.readbyqxmd.com/read/27802176/complex-effects-of-apoplexy-secondary-to-pituitary-adenoma
#20
Rui-Cheng Zhang, Ying-Feng Mu, Jing Dong, Xiao-Qian Lin, De-Qin Geng
Pituitary adenoma apoplexy is a well-known clinical syndrome induced by insulin infusion, cardiac surgery, trauma, and hypothalamic releasing factors. Pituitary apoplexy can cause secondary cerebral infarct and internal carotid artery occlusion. With blockade of tumor perfusion, apoplexy triggers a sudden onset of headache, visual impairment, cranial nerve palsy, disturbances of consciousness, eyelid ptosis, and hemiparesis. However, pituitary adenoma cells with high metabolic demand cannot survive with deficient blood supply and glucose concentrations...
October 29, 2016: Reviews in the Neurosciences
keyword
keyword
12770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"